Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | SCN1A | P35498 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5857743 | 0.93 | KEAP1 (0.58) | KEAP1SMN1; SMN2HPGDDUSP3ALDH1A1 | |
| SCHEMBL21527101 | 0.91 | KEAP1 (0.52) | KEAP1SMN1; SMN2HPGDDUSP3ALDH1A1 | |
| SCHEMBL5858975 | 0.91 | KEAP1 (0.56) | KEAP1SMN1; SMN2HPGDDUSP3ALDH1A1 | |
| SCHEMBL5860507 | 0.91 | KEAP1 (0.56) | KEAP1SMN1; SMN2HPGDDUSP3ALDH1A1 | |
| SCHEMBL297745 | 0.84 | — | — | |
| SCHEMBL1998867 | 0.84 | KEAP1 (0.71) | KEAP1SMN1; SMN2HPGDDUSP3ALDH1A1 | |
| SCHEMBL7239607 | 0.84 | KEAP1 (0.71) | KEAP1SMN1; SMN2HPGDDUSP3ALDH1A1 | |
| SCHEMBL8413740 | 0.82 | KDM4E (0.50) | KEAP1SMN1; SMN2HPGDDUSP3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL9433012 | 0.82 | KDM4E (0.50) | KEAP1SMN1; SMN2HPGDDUSP3ALDH1A1 | |
| SCHEMBL9740021 | 0.81 | KEAP1 (0.68) | KEAP1SMN1; SMN2HPGDDUSP3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186543-A1 | CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL, INC. | 2025-06-12 | — | — | US | disclosed |
| CN-118324867-A | Novel cyclosporin derivatives and uses thereof | 美国科技环球有限公司 | 2024-07-12 | — | — | CN | disclosed |
| EP-4374877-A2 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-29 | — | — | EP | disclosed |
| CN-114423742-B | Benzotriazole-based compound, light absorber and resin composition | 三井化学株式会社 | 2024-05-28 | — | — | CN | disclosed |
| EP-3928779-B1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2024-03-06 | — | — | EP | disclosed |
| CN-109476705-B | Novel cyclosporin derivatives and uses thereof | 美国科技环球有限公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-117466830-A | Benzotriazole-based compound, light absorber and resin composition | 三井化学株式会社 | 2024-01-30 | — | — | CN | disclosed |
| WO-2024005030-A1 | DIPHENYLETHENE-BASED COMPOUND, LIGHT ABSORBER, RESIN COMPOSITION, AND USE THEREOF | 山本化成株式会社 | 2024-01-04 | — | — | WO | disclosed |
| WO-2023164233-A1 | (4-BENZO[D]OXAZOL-2-YL)-6,7-DIHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE-5(4H)-YL)METHANONE DERIVATIVES AS MUTANT PAH STABILIZERS FOR THE TREATMENT OF PHENYLKETONURIA | AGIOS PHARMACEUTICALS, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| US-20220331397-A1 | CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. | 2022-10-20 | — | — | US | disclosed |
| EP-0676237-B1 | Modified ion exchange resins and use thereof | MITSUBISHI CHEM CORP (JP) | 1999-03-17 | — | — | EP | disclosed |
| WO-1998013354-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 1998-04-02 | — | — | WO | disclosed |
| US-5589517-A | N,N-DI-SUBSTITITUTED MERCAPTOALKYLAMINE SULFONIC ACID ION EXCHANGE RESIN AS CATALYST FOR CONDENSATION REACTION OF A PHENOL AND A KETONE TO PRODUCE A BISPHENOL | MITSUBISHI CHEMICAL CORPORATION (JP) | 1996-12-31 | — | — | US | disclosed |
| EP-0676237-A1 | Modified ion exchange resins and use thereof | MITSUBISHI CHEMICAL CORPORATION (JP) | 1995-10-11 | — | — | EP | disclosed |
| EP-0658162-A1 | CARBAPENEM DERIVATIVES AND PROCESSES FOR PREPARING THE SAME | DONG-A PHARM. CO., LTD. (KR) | 1995-06-21 | — | — | EP | disclosed |
| WO-1994005667-A1 | CARBAPENEM DERIVATIVES AND PROCESSES FOR PREPARING THE SAME | DONG-A PHARMACEUTICAL CO., LTD. (KR) | 1994-03-17 | — | — | WO | disclosed |
| WO-1994003791-A1 | METABOLIC MONITORING OF CELLS IN A MICROPLATE READER | MOLECULAR DEVICES CORPORATION (US) | 1994-02-17 | — | — | WO | disclosed |
| EP-0289262-A2 | Omega-quaternary ammonium alkyl esters and thioesters of acidic nonsteroidal antiinflammatory drugs | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1988-11-02 | — | — | EP | disclosed |
| US-4281118-A | Aminoalkylsulfides, aminoalkylsulfoxides, and aminoalkylsulfones | THE DOW CHEMICAL COMPANY (US) | 1981-07-28 | — | — | US | disclosed |
| US-4281118-A | Aminoalkylsulfides, aminoalkylsulfoxides, and aminoalkylsulfones | THE DOW CHEMICAL COMPANY (US) | 1981-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186543-A1 | CYCLOSPORIN DERIVATIVES AND USES THEREOF | MALT1, MTPN, MYLK2 | KEAP1 3820/4885SMN1; SMN2 431/4885HPGD 3555/4885 |
| US-20220331397-A1 | CYCLOSPORIN DERIVATIVES AND USES THEREOF | MALT1, MTPN, MYLK2 | KEAP1 3820/4885SMN1; SMN2 431/4885HPGD 3555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.